南通地区XRCC1基因多态性与肝癌患者TACE疗效及预后的关系  

The relationship between XRCC1 gene polymorphism and the efficacy and prognosis of TACE in patients with hepatocellular carcinoma in Nantong area

作　　者：陆小华[1] 袁洪新[1] 赵辉[1] 朱小庆[1] LU Xiaohua;YUAN Hongxin;ZHAO Hui;ZHU Xiaoqing(Department of Interventional Radiology,Affiliated Hospital of Nantong University,Nantong,Jiangsu 226001,China)

机构地区：[1]南通大学附属医院介入放射科,江苏南通226001

出　　处：《公共卫生与预防医学》2021年第5期101-104,共4页Journal of Public Health and Preventive Medicine

基　　金：南通市科技局2018年度基础科学研究项目(JC2018138)。

摘　　要：目的了解XRCC1基因C26304T、G27466A、G28152A位点单核苷酸多态性(SNP)的分布特点,探讨上述位点各基因型与肝细胞癌TACE疗效及预后的关系,从中发现与TACE疗效及预后相关的多态性位点,作为预估TACE疗效及预后的生物标记物。方法选择2018年1月1日至2019年12月31日在南通大学附属医院介入放射科住院的252例初诊肝癌患者,提取基因组DNA,收集相关临床资料及腹部增强CT/MRI资料。利用panel高通量数据分析进行基因分型。所有患者均行TACE治疗,治疗后4~6周复查腹部增强CT/MRI,按照RECIST实体瘤疗效评定判断疗效。15个月后电话随访入组者生存情况。对比不同TACE治疗疗效及预后中各基因型的频率分布差异,以比值比(OR)及其95%可信区间(CI)表示相关基因型与肝癌TACE疗效及预后的关联强度。结果(1)XRCC1基因G28152A位点杂合突变基因型AG患者较野生型GG患者TACE疗效更好(OR=0.294,95%CI:0.053~0.987),而携带纯合突变基因型AA患者与野生型GG患者比较,TACE疗效差异无统计学意义(OR=1.334,95%CI:0.123~8.545)。C26304T、G27466A位点各基因型之间TACE疗效差异无统计学意义。(2)XRCC1基因G28152A位点杂合突变基因型AG患者较野生型GG患者生存期更长,TACE预后更好(OR=0.262,95%CI:0.051~0.988),而携带纯合突变基因型AA患者与野生型GG患者比较,生存期差异无统计学意义(OR=2.180,95%CI:0.312~12.743)。C26304T、G27466A位点各基因型之间生存期差异无统计学意义。结论携带XRCC1基因G27466A位点杂合突变基因型AG的南通地区肝癌患者TACE疗效及预后更好,C26304T位点、G28152A位点SNP与TACE疗效及预后无明显关联。Objective To investigate the relationship between the genotypes of XRCC1 gene C26304T,G27466A,G28152A and the efficacy and prognosis of hepatocellular carcinoma in Nantong area.Methods The Genomic DNA was extracted from 252 newly diagnosed liver cancer patients admitted to the Department of Interventional Radiology,Affiliated Hospital of Nantong University from January 1,2018 to December 31,2018,and relevant clinical data and abdominal enhanced CT/MRI data were collected.Genotyping was performed using Panel high-throughput data analysis.All patients received TACE treatment,and abdominal enhanced CT/MRI was reexamined 4-6 weeks after treatment,and the efficacy was evaluated according to the efficacy of RECIST solid tumor.Survival of participants was followed up by telephone after 15 months.The frequency distribution differences of different genotypes in the efficacy and prognosis of different TACE treatments were compared,and the strength of association between related genotypes and the efficacy and prognosis of HCC TACE was indicated by odds ratio(OR)and its 95%confidence interval(CI).Results 1.The efficacy of TACE was better in AG patients with XRCC1 G28152A heterozygous mutation(OR=0.294,95%CI:0.053-0.987),while there was no significant difference between patients with homozygous AA and patients with wild-type GG(OR=1.334,95%CI:0.123-8.545).There was no significant difference in the efficacy of TACE between C26304T and G27466A genotypes.2.Compared with the patients with wild-type GG,patients with G28152A heterozygous mutation AG were more likely to survive for 15 months and had a better prognosis after TACE(OR=0.262,95%CI:0.051-0.988),but there was no significant difference in survival time between patients with homozygous mutation AA and patients with wild-type GG(OR=2.180,95%CI:0.312-12.743).There was no significant difference in survival time between the genotypes of C26304T and G27466A.Conclusion The patients with liver cancer in Nantong who carried heterozygous mutation AG at G27466A site of XRCC1 gene had

关 键 词：XRCC1基因 多态性 肝癌 经导管动脉化疗栓塞(TACE) 

分 类 号：R181[医药卫生—流行病学]